Standout Papers

Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyse... 2023 2026 2024176
  1. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial (2023)
    Yelena Y. Janjigian, Akihito Kawazoe et al. The Lancet

Immediate Impact

3 standout
Sub-graph 1 of 2

Citing Papers

Tumor immunotherapy resistance: Revealing the mechanism of PD-1 / PD-L1-mediated tumor immune escape
2024 Standout
Oesophageal cancer
2024 Standout
1 intermediate paper

Works of Yuriy Ostapenko being referenced

Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial
2023 Standout
Patient-reported outcomes from the phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.
2022

Author Peers

Author Last Decade Papers Cites
Yuriy Ostapenko 113 128 63 6 188
Shu-Kui Qin 175 122 43 8 259
Ester Simeone 126 137 173 6 289
Evgeny Gotovkin 113 149 74 4 199
Sam Li‐Sheng Chen 120 141 142 6 281
Mark Sievert 84 157 91 4 208
Kazuhiko Shioji 105 188 150 11 271
Kanwal Pratap Singh Raghav 157 115 60 8 233
Arnoud H. A. M. van Oijen 124 160 204 7 297
Kevin K. Chang 101 200 80 12 268
E Volpin 99 35 65 5 151

All Works

Loading papers...

Rankless by CCL
2026